Advocate Medical Group — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$15	1
2024	Research	$3,311	2
2023	Research	$10,863	2
2022	Research	$24,192	1
2021	Research	$588	2
2020	Research	$5	1

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $37,366 4 payments
Celgene Corporation $1,000 1 payment
AstraZeneca Pharmaceuticals LP $588 2 payments
Pfizer Inc. $15 1 payment
Amgen Inc. $5 1 payment

Studies the money was for Research payments · program years 2020–2025

Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) $28,476 2 payments
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $8,890 2 payments
Celgene Connect Myeloid Disease Registry $1,000 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $588 2 payments
An Interventional Openlabel Randomized Multicenter Phase 2 Study of Pf07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years Or Older With Hormone Receptorpositive Her2negative Breast Cancer in the Neoadjuvant Setting $15 1 payment
Galactic - HF $5 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.